Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07498959 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Study acronym: TESTIGO
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Trial Details
NCT Number NCT07498959
Lead Sponsor Sahlgrenska University Hospital
Collaborators: Karolinska University Hospital, Haukeland University Hospital, University Hospital of North Norway, Oslo University Hospital, Trondheim University Hospital, Uppsala University Hospital, University Hospital, Umeå, Lund University Hospital
Conditions
(from sponsor)		 Testicular Cancer, Seminoma, Quality of Life, De-escalation, RPLND
Related terms Seminoma, Testicular Neoplasms
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov